Patients’ Characteristics
| Patient no. | Sex | Age (y) | Disease | Previous lines of therapy | Conditioning regimen | Additional radioimmunotherapy | RLT to neutropenia | SCT to neutrophil reconstitution | Best response | Progression-free survival | Overall survival |
| 1 | M | 62 | DLBCL | 2 | Fludarabine, busulfan, thiotepa, ATG | No | 8 | 9 | NA | 29 | 29 |
| 2 | F | 46 | DLBCL | 3 | Fludarabine, busulfan, thiotepa | No | 15 | 10 | Mixed | 110 | 334 |
| 3 | F | 64 | DLBCL | 5 | Fludarabine, busulfan, thiotepa, ATG | No | 7 | NA | NA | 34 | 34 |
| 4 | M | 47 | DLBCL | 3 | Fludarabine, busulfan, thiotepa, ATG | No | 7 | 13 | Mixed | 34 | 62 |
| 5 | F | 52 | DLBCL | 3 | Busulfan, thiotepa, ATG | Yes (188Re-anti-CD66) | 5 | 13 | PR | 89 | 89 |
| 6 | M | 55 | DLBCL | 6 | Fludarabine, treosulfan, thiotepa, ATG | Yes (90Y-Zevalin) | 20 | 11 | PR | 109 | 115 |
ATG = antithymocyte globulin; NA = not applicable.
All time intervals are given in days.